Furthermore, many studies have found that increased AVP release (assessed by measuring the surrogate precursor product copeptin) predicts insulin resistance and the onset of type 2 diabetes and major cardiovascular events in metabolic syndrome patients [[16], [17], [18], [19]]. Here, AVP is linked to metabolic syndrome.